Clinical Trial Update: Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes a study of apatinib in combination with docetaxel as second-line therapy for advanced non-squamous non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN